Leaflet STRIVERDI RESPIMAT 2.5mcg inhalation solution


Indicated for: chronic obstructive pulmonary disease

Route of administration: inhalation

Substance: olodaterol (beta-2 adrenergic agonist)

ATC: R03AC19 (Respiratory system | Adrenergics, inhalants | Selective beta-2-adrenoreceptor agonists)

Olodaterol is a long-acting beta-2 adrenergic agonist used for the treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It works by relaxing the smooth muscles of the airways, making breathing easier.

The medication is administered via an inhaler, usually once daily, as directed by a doctor. It is important for patients to use the medication regularly to achieve maximum benefits.

Patients should be aware of potential side effects, such as tremors, palpitations, or headaches. It is important to inform the doctor of any unusual symptoms.

Common side effects include tremors, palpitations, headaches, and dry mouth. In rare cases, severe reactions such as paradoxical bronchospasm or allergic reactions may occur. Patients should be informed of these risks before starting treatment.

General data about STRIVERDI RESPIMAT 2.5mcg

  • Substance: olodaterol
  • Date of last drug list: 01-07-2021
  • Commercial code: W60771005
  • Concentration: 2.5mcg
  • Pharmaceutical form: inhalation solution
  • Quantity: 3
  • Product type: original
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG - GERMANIA
  • Holder: BOEHRINGER INGELHEIM INTERNATIONAL GMBH - GERMANIA
  • Number: 11140/2018/02
  • Shelf life: 3 years-; after the first opening a cartusului - 3 months; dupa prima utilizare a inhalatorului- 1an

Combinations with other substances